Use of the Hansen Medical System in Patients With Paroxysmal Atrial Fibrillation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01122173 |
Recruitment Status :
Terminated
First Posted : May 13, 2010
Results First Posted : September 11, 2018
Last Update Posted : September 11, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Paroxysmal Atrial Fibrillation | Device: Ablation | Not Applicable |
Subjects who satisfy the inclusion and exclusion criteria will be treated with an RF ablation catheter and Artisan guide catheters controlled by the Sensei X Robotic Catheter System.
Subject will be followed for a period of one year post ablation procedure.
Follow up visit time frames will be conducted at 7-day, 30-day, 90-day, 180-day and 365-day.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 150 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Prospective, Single Arm Study of the Hansen System for Introducing and Positioning RF Ablation Catheters in Subjects With Paroxysmal Atrial Fibrillation |
Study Start Date : | July 2013 |
Actual Primary Completion Date : | April 2017 |
Actual Study Completion Date : | April 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Robotic catheter manipulation, Ablation
To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
|
Device: Ablation
Atrial fibrillation ablation procedure
Other Names:
|
- Safety-Incidence of Major Complications [ Time Frame: within 7 days of the ablation procedure nd the incidence of esophageal injury or pulmonary vein stenosis through 180 days ]The primary safety endpoint was defined as the incidence of major complications, including all early onset (within 7 days of the ablation procedure) major complications, and the incidence of esophageal injury or pulmonary vein stenosis through 180 days.
- Effectiveness-Freedom From Symptomatic Atrial Fibrillation (AF), Atrial Flutter, and Atrial Tachycardia Episodes [ Time Frame: 91 - 365 days after the inital ablation procedure ]The primary effectiveness endpoint is chronic success as demonstrated by the freedom from symptomatic atrial arrhythmia from days 91 to 365.
- Acute Procedural Success [ Time Frame: Day 0 ]Acute procedural success is defined as the successful ablation of at least three of four pulmonary veins as shown by pulmonary vein entrance block per vein during the initial ablation procedure. A subject is considered to be an acute procedural failure if acute procedural success cannot be obtained by using the Hansen system and, as a result, manual manipulation is needed to complete the ablation procedure with the ablation catheter.
- Chronic Safety-Incidence of Major Complications [ Time Frame: 8 - 365 days post-procedure ]Chronic safety is defined as the incidence of Major Complications during the period from 8 - 365 days following the initial ablation procedure (excluding pulmonary vein stenosis and atrio-esophageal fistula from 8 - 180 days, which are included in the primary safety endpoint). The incidence of pulmonary vein stenosis and atrioesophageal fistula is included during the period from 181 - 365 days.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with paroxysmal atrial fibrillation who have had two or more spontaneously terminating episodes of atrial fibrillation, that last longer than 30 seconds and shorter than 7 days, in the nine months prior to enrollment. At least one episode must be documented with EKG, TTM, Holter monitor, or telemetry.
- Failure of at least one Class I - IV anti-arrhythmic drug (AAD) for PAF as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AADs. AADs are defined in Appendix B.
- Signed informed consent.
- Age 18 years or older
- Able and willing to comply with all pre-, post-, and follow-up testing and requirements.
Exclusion Criteria:
- Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- Previous ablation for atrial fibrillation.
- Atrial fibrillation episodes that last less than 7 days and are terminated by cardioversion.
- Previous valvular cardiac surgery procedure.
- Cardiac artery bypass graft procedure within the previous 180 days.
- Previous septal defect repair.
- Expecting cardiac transplantation or other cardiac surgery within the next 180 days.
- Coronary PTCA/stenting within the previous 180 days.
- Documented left atrial thrombus on ultrasound imaging (TEE).
- Documented history of a thrombo-embolic event within the previous 365 days.
- Diagnosed atrial myxoma.
- Presence of an implanted ICD.
- Presence of permanent pacing leads.
- Significant restrictive, constrictive, or chronic obstructive pulmonary disease or any other disease or malfunction of the lungs or respiratory system with chronic symptoms.
- Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
- Women who are pregnant.
- Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11,000 mm3) for which antibiotics have been or will be prescribed.
- Creatinine > 2.5 mg/dl (or > 221 µmol/L).
- Unstable angina.
- Myocardial infarction within the previous 60 days.
- Left ventricular ejection fraction less than 40%
- History of blood clotting or bleeding abnormalities.
- Contraindication to anticoagulation medications.
- Contraindication to computed tomography or magnetic resonance imaging procedures.
- Life expectancy less than 1 year.
- Enrollment in another investigational study.
- Uncontrolled heart failure (NYHA class III or IV heart failure).
- Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.
- Presence of a condition that precludes vascular access.
- Left atrial size ≥ 50mm.
- INR greater than 3.0 within 24 hours of procedure.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01122173
United States, Arizona | |
Banner Heart Hospital | |
Mesa, Arizona, United States, 85206 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, New Jersey | |
Englewood Hospital and Medical Center | |
Englewood, New Jersey, United States, 07631 | |
Saint Barnabas Heart Center | |
Livingston, New Jersey, United States, 07039 | |
United States, South Carolina | |
Greenville Memorial Hospital | |
Greenville, South Carolina, United States, 29605 | |
United States, Texas | |
Texas Health Arlington Memorial/Heart Place | |
Arlington, Texas, United States, 76012 | |
Texas Cardiac Arrhythmia Research Foundation (TCARF) | |
Austin, Texas, United States, 78705 | |
Houston Methodist Research Institute | |
Houston, Texas, United States, 77030 | |
United States, Virginia | |
Univeristy of Virginia | |
Charlottesville, Virginia, United States, 22908 | |
Czechia | |
IKEM, Dept of Cardiology | |
Prague, Czechia | |
Denmark | |
Gentofte University Hospital | |
Hellerup, Denmark, 2900 | |
Spain | |
Hospital Universitario Madrid Montepríncipe | |
Madrid, Spain | |
United Kingdom | |
John Radcliff Hospital | |
Oxford, United Kingdom, OX39DU |
Principal Investigator: | Joseph Gallinghouse, M.D. | Texas Cardiac Arrhythmia Research Foundation | |
Principal Investigator: | Andrea Natale, M.D. | Texas Cardiac Arrhythmia Research Foundation | |
Study Director: | Brenda Cayme, RN., BSN | Hansen Medical, Inc. |
Documents provided by Hansen Medical:
Responsible Party: | Hansen Medical |
ClinicalTrials.gov Identifier: | NCT01122173 |
Other Study ID Numbers: |
HMP010 |
First Posted: | May 13, 2010 Key Record Dates |
Results First Posted: | September 11, 2018 |
Last Update Posted: | September 11, 2018 |
Last Verified: | August 2018 |
Atrial Fibrillation Robotic Control Remote Control |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |